ArticleEndocrine2025
Detection rate and clinical characteristics of coexisting autoimmune diseases in children with Graves' disease: a single-center study from China.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to determine the detection rate of autoimmune polyendocrine syndrome (APS) among children with Graves' disease (GD) at a single center and to compare clinical characteristics between those with isolated GD and those GD with APS (APS-GD).
methodsA retrospective analysis was conducted on the clinical data of 555 patients and were categorized into isolated GD and APS-GD groups based on their progression status. The time for FT
resultsIn all, 63 (11.4%) had coexisting APS; 52 (82.5%) were female. The most common component of APS was type 1 diabetes mellitus (T1DM) [24 (4.3%)]. Among APS-GD patients, after the diagnosis of the first component, the cumulative incidences of a second disease within the first, second, and third years were 63.4%, 74.6%, and 82.0%, respectively and till the end of the first decade reached 95.0%. The isolated GD group had higher levels of FT
conclusionThe study uncovered a high comorbidity rate of APS in children with GD, suggesting that patients with APS-GD have a higher risk of progression to additional endocrine gland disorders. Yet, both groups showed no significant difference in their short-term therapeutic response. These findings are crucial for guiding the clinical management and follow-up of pediatric GD patients.
Indexed as
Identifiers
39762666What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.